ASPIRE-LAKEWOOD HOLDINGS INC
ASBPNASDAQTrading Snapshot
- Day Range
- $8.56 – $8.93
- 52-Week Range
- $0.11 – $562.80
- Volume (shares)
- 13,937
- Avg Volume (shares)
- —
- Shares Outstanding
- 115,371
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $6,202
- Last Q Revenue
- $63,103
- P/E Ratio
- -1.1
- P/S Ratio
- 10.5x
- EPS (TTM)
- $-10.65
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +6399.8%
ASPIRE-LAKEWOOD HOLDINGS INC
ASBP
StockOtter · stockotter.spaceAbout ASPIRE-LAKEWOOD HOLDINGS INC
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program
Brings total authorized repurchase to $10 million Reflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunity Increased authorization su
Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.
ESTERO, FL / ACCESS Newswire / September 8, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "Aspire Biopharma Holdings, Inc."
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at S
Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue
Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets
Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9% – Time to Buy?
Shares of Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP - Get Free Report) rose 10.9% on Monday. The stock traded as high as $7.44 and last traded at $7.23. 27,396 shares changed hands during trading, a decline of 49% fr